Italia markets open in 34 minutes

Moleculin Biotech, Inc. (0K2H.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,4000+0,0850 (+6,46%)
Alla chiusura: 03:46PM GMT

Moleculin Biotech, Inc.

5300 Memorial Drive
Suite 950
Houston, TX 77007
United States
713 300 5160
https://www.moleculin.com

Settore/i
Settore
Impiegati a tempo pieno13

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Walter V. KlempFounder, Chairman, Pres & CEO891,66kN/D1960
Mr. Jonathan P. Foster CPAExec. VP & CFO611,2kN/D1964
Dr. Donald H. Picker Ph.D.Chief Scientific Officer479,87kN/D1946
Dr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory BoardN/DN/DN/D
Dr. Robert C. Shepard FACP, M.D., F.A.C.P.Chief Medical Officer of AnnamycinN/DN/D1952
Dr. John Paul Waymack M.D., Sc.D.Sr. Chief Medical OfficerN/DN/D1952
Dr. Sandra L. Silberman M.D., Ph.D.Chief Medical Officer of New ProductsN/DN/D1955
Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D.European Chief Medical OfficerN/DN/DN/D
Ms. Jacqueline NorthcutConsultantN/DN/D1962
Mr. Louis Ploth Jr.Independent AdvisorN/DN/D1954
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Governance aziendale

L'ISS Governance QualityScore di Moleculin Biotech, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.